1-(2-naphthalenyl)-3-[(phenylmethyl)-propan-2-ylamino]-1-propanone has been researched along with Machado-Joseph Disease in 1 studies
ZM39923: structure in first source
Machado-Joseph Disease: A dominantly-inherited ATAXIA first described in people of Azorean and Portuguese descent, and subsequently identified in Brazil, Japan, China, and Australia. This disorder is classified as one of the SPINOCEREBELLAR ATAXIAS (Type 3) and has been associated with a mutation of the MJD1 gene on chromosome 14. Clinical features include progressive ataxia, DYSARTHRIA, postural instability, nystagmus, eyelid retraction, and facial FASCICULATIONS. DYSTONIA is prominent in younger patients (referred to as Type I Machado-Joseph Disease). Type II features ataxia and ocular signs; Type III features MUSCULAR ATROPHY and a sensorimotor neuropathy; and Type IV features extrapyramidal signs combined with a sensorimotor neuropathy. (From Clin Neurosci 1995;3(1):17-22; Ann Neurol 1998 Mar;43(3):288-96)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lai, TS | 1 |
| Liu, Y | 1 |
| Tucker, T | 1 |
| Daniel, KR | 1 |
| Sane, DC | 1 |
| Toone, E | 1 |
| Burke, JR | 1 |
| Strittmatter, WJ | 1 |
| Greenberg, CS | 1 |
1 other study available for 1-(2-naphthalenyl)-3-[(phenylmethyl)-propan-2-ylamino]-1-propanone and Machado-Joseph Disease
| Article | Year |
|---|---|
Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries.
Topics: Animals; Calcium; Combinatorial Chemistry Techniques; Disease Models, Animal; Drosophila melanogaste | 2008 |